Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells

被引：0
|
作者：
Patrick R. Merz
Nina Röckel
Seda Ballikaya
Gerd U. Auffarth
Ingo Schmack
机构：
[1] University of Heidelberg,Department of Ophthalmology
[2] Lions Eye Bank,Department of Ophthalmology
[3] Goethe-University Frankfurt,undefined
来源：
BMC Ophthalmology | / 18卷
关键词：
Corneal neovascularization; Corneal endothelial cells; Corneal angiogenesis; Vascular endothelial growth factor; Ranibizumab; Bevacizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
    Merz, Patrick R.
    Roeckel, Nina
    Ballikaya, Seda
    Auffarth, Gerd U.
    Schmack, Ingo
    BMC OPHTHALMOLOGY, 2018, 18
  • [2] Corneal Neovascularization and the Utility of Topical VEGF Inhibition: Ranibizumab (Lucentis) Vs Bevacizumab (Avastin)
    Stevenson, William
    Cheng, Sheng-Fu
    Dastjerdi, Mohammad H.
    Ferrari, Giulio
    Dana, Reza
    OCULAR SURFACE, 2012, 10 (02): : 67 - 83
  • [3] Lucentis (Ranibizumab) versus Avastin (Bevacizumab) for CNV/AMD
    Naomi, Fischer
    Rodrigo, Jung
    Gadi, Heilweil
    David, Varssano
    Michaella, Goldstein
    Adiel, Barak
    Anat, Loewenstein
    8TH INTERNATIONAL SYMPOSIUM ON OCULAR PHARMACOLOGY AND THERAPEUTICS - ISOPT, 2009, : 65 - 68
  • [4] Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
    Raftery, James
    Clegg, Andrew
    Jones, Jeremy
    Tan, Seng Chuen
    Lotery, Andrew
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2007, 91 (09) : 1244 - 1246
  • [5] BEVACIZUMAB (AVASTIN) AND RANIBIZUMAB (LUCENTIS) FOR CHOROIDAL NEOVASCULARIZATION IN MULTIFOCAL CHOROIDITIS
    Fine, Howard F.
    Zhitomirsky, Inna
    Freund, K. Bailey
    Barile, Gaetano R.
    Shirkey, Belinda L.
    Samson, C. Michael
    Yannuzzi, Lawrence A.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (01): : 8 - 12
  • [6] Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells
    Spitzer, Martin S.
    Yoeruek, Efdal
    Sierra, Ana
    Wallenfels-Thilo, Barbara
    Schraermeyer, Ulrich
    Spitzer, Bernhard
    Bartz-Schmidt, Karl U.
    Szurman, Peter
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2007, 245 (12) : 1837 - 1842
  • [7] Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells
    Martin S. Spitzer
    Efdal Yoeruek
    Ana Sierra
    Barbara Wallenfels-Thilo
    Ulrich Schraermeyer
    Bernhard Spitzer
    Karl U. Bartz-Schmidt
    Peter Szurman
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245 : 1837 - 1842
  • [8] Association of ranibizumab (Lucentis®) or bevacizumab (Avastin®) with dexamethasone and triamcinolone acetonide: An in vitro stability assessment
    Veurink, Marieke
    Stella, Cinzia
    Tabatabay, Cyrus
    Pournaras, Constantin J.
    Gurny, Robert
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2011, 78 (02) : 271 - 277
  • [9] Safety Profile Comparison Between Topical Pegaptanib (Macugen®), Bevacizumab (Avastin®) and Ranibizumab (Lucentis®)
    Bucher, F.
    Bock, F.
    Hos, D.
    Cursiefen, C.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [10] Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation
    Hufendiek K.
    Hufendiek K.
    Panagakis G.
    Helbig H.
    Gamulescu M.-A.
    International Ophthalmology, 2012, 32 (3) : 259 - 268
12345